+852 2866 8995 General Enquiry: cs@medikonia.com | Support: support@medikonia.com

Cytek violetFluor™ 450 Anti-Human CD11c (3.9)

violetFluor™ 450 Anti-Human CD11c (3.9)

Product description Order information Resources Panel

Description

The 3.9 antibody reacts with human CD11c, also known as integrin αalpha X. This 150 kDa cell surface glycoprotein is part of a family of integrin αreceptors that mediate adhesion between ≥ ≥ ≥ cells (cell-cell) and components of the extracellular matrix, e.g. fibrinogen (cell-matrix). In addition, integrin αs are active signaling receptors which recruit leukocytes to inflammatory sites and promote cell activation. Complete, functional integrin αreceptors consist of distinct combinations of integrin αchains which are differentially expressed. integrin αalpha X (CD11c) assembles with integrin αbeta-2 (CD18) into a receptor known as CR4 which can bind and induce signaling through ICAMs and VCAM-1 on endothelial cells and can also facilitate removal of iC3b bearing foreign cells.

The 3.9 antibody is widely used as a marker for CD11c expression on dendritic cells (DC), often in parallel with markers for CD11b, for identification of developmental stages and mature subsets of this cell type. CD11c is prominently expressed on tissue macrophages, and is also detected on activated neutrophils, granulocytes, some types of activated T cells and intestinal intraepithelial lymphocytes (IEL). The antibody is reported to be cross-reactive with Baboon, Chimpanzee, Cynomolgus and Rhesus CD11c.

 

 

Name

violetFluor™ 450 Anti-Human CD11c (3.9)

Cat. No.

75-0116

Alternative Names 

CR4, integrin αX, ITGAX

Gene ID

3687

Clone

3.9

Isotype

Mouse IgG1, kappa

Reactivity

Human

Cross Reactivity

Baboon, Chimpanzee, Cynomolgus, Rhesus

Format

violetFluor™ 450

Application

Flow Cytometry

Catalog #: 75-0116-T025 -- 25 tests

Catalog #: 75-0116-T100 -- 100 tests

 

Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.